Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Key benefits Why people compare it 1 22.5% mean body weight reduction at 15mg in SURMOUNT-1 (N=2,539, 72 weeks) 2 Dual GIP/GLP-1 receptor activation for combined metabolic effects beyond single-agonist therapy 3 63% of participants at highest dose achieved at least 20% weight loss vs 1.3% placebo 4 Superior A1C reduction of 2.07-2.59% with up to 97% of diabetic participants reaching target 5 Outperformed semaglutide 1mg head-to-head in SURPASS-2 for both weight and glycemic endpoints 6 Enhanced adipose tissue lipid handling and fat redistribution via GIPR signaling 7 Significant improvements in triglycerides, blood pressure, and waist circumference across all doses 8 Once-weekly dosing supported by 120-hour half-life and C20 fatty diacid albumin binding Deep research Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight of 4,813.45 Da
Are you afraid of falling when you stand up or try to walk
Beneficiaries must be enrolled in a Part D plan Medicare Part D beneficiaries must be enrolled in a Part D PDP or MA-PD plan for calendar year 2026 to qualify to receive GLP-1s under the Bridge Program
To understand whether compounded formulations work differently from brand-name options, you need to know why these alternatives exist and what complicates their legal status
Pharmacy and Therapeutics, 35 (9), 498
Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis
US$ 24.36
US$ 28.58
US$ 22.50
